Solid Biosciences received the Food and Drug Administration's fast-track designation for a gene therapy intended to treat a condition known as Friedreich's ataxia. Solid Biosciences will move the ...
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE ...
These disorders include: celiac disease non-celiac gluten sensitivity gluten ataxia, (an autoimmune disorder that may cause neurological symptoms, including issues with balance, motor control ...
A ataxia de Friedreich afeta aproximadamente 5.000 pessoas nos Estados Unidos e 15.000 na Europa. Atualmente, não existem tratamentos que possam curar ou interromper a progressão da doença. A Solid ...
Friedreich ataxia, an autosomal recessive neurodegenerative disease, is the most common of the inherited ataxias. The recent discovery of the gene that is mutated in this condition,FRDA, has led to ...
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% ...
The Senate confirmed former Fox News host and combat veteran Pete Hegseth as defense secretary in a tense late-night session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback